- Company
- 10 years since stem cell therapy was introduced
- by Chon, Seung-Hyun Jun 3, 2022 06:36am
- Ten years have passed since stem cell treatments appeared in Korea, but they have yet to produce commercial results. Medipost's CARTISTEM is recording annual sales of 10 billion won in Korea, but there is virtually no overseas sales. According to the Financial Supervisory Service on the 2nd, Medipost's sales of stem cell treatments in the
- Company
- Dukarb of Huons won the patent battle
- by Kim, Jin-Gu Jun 3, 2022 06:36am
- Given that Boryung won a series of previous referees, the pharmaceutical industry is paying keen attention to the decision, which is the opposite of the previous one. ◆Patent judge decides opposite to previous judgment According to the pharmaceutical industry on the 2nd, the Korean Intellectual Property Tribunal made a claim c
- Company
- Commercialization of ADC Enhertu is imminent in Korea
- by Eo, Yun-Ho Jun 2, 2022 05:58am
- The HER2-directed antibody-drug conjugate (ADC) ‘Enhertu’ is expected to be commercialized in Korea soon. According to inducts sources, Daiichi Sankyo Korea and AstraZeneca Korea’s human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) ‘Enhertu (trastuzumab deruxtecan),’ is expected to be approved withi
- Company
- Evusheld to be introduced in Korea
- by Eo, Yun-Ho May 31, 2022 06:06am
- The introduction of the COVID-19 prevention drug Evusheld in Korea has been confirmed. The KDCA supplementary budget of 4.9083 trillion won was confirmed yesterday (29th), which includes securing a shortage of living support, paid vacation expenses, quarantine hospitalization, and home treatment expenses due to a surge in confirmed cases. The
- Company
- Handok to “speed up global P2T for its BTC candidate"
- by Kim, Jin-Gu May 31, 2022 06:05am
- Handok Pharmaceuticals announced on the 30th that it had recently received approval to change the clinical trial protocol for its candidate, 'ABL001(CTX-009),' which the company is developing as a treatment for biliary tract cancer, to expand the trial overseas into a global clinical trial. ABL001 is a next-generation anticancer drug that
- Company
- PalPal's sales are 5.1 billion won
- by Kim, Jin-Gu May 31, 2022 06:05am
- Hanmi Pharmaceutical is about to win the market for erectile dysfunction treatments. While "PalPal," the No. 1 item in the existing market, was leading, third-place Gugu chased second-place Chong Kun Dang's Cendom. According to IQVIA, a pharmaceutical market research institute, on the 28th, the domestic erectile dysfunction treatment marke
- Company
- Obesity treatment market expands 66% in 4 yrs
- by Chon, Seung-Hyun May 30, 2022 05:42am
- The obesity treatment market continues to grow with the launch of new products. The size of the new market has expanded by more than 60% over the past four years. According to IQVIA, a pharmaceutical research institute, on the 29th, the size of the obesity treatment market in the first quarter was 35.7 billion won, up 11.3% year-on-year. The
- Company
- Interleukin inhibitor market doubles in 2 years
- by May 30, 2022 05:41am
- Sales of interleukin inhibitors that are used to treat autoimmune diseases such as psoriasis have increased over twofold in 2 years. 1st generation drugs including Stelara, Cosentyx, Tremfya, and Skyrizi have all shown even growth. Market analysts have evaluated that the use of IL inhibitors has increased with the steady expansion of their indic
- Company
- Samjin recently filed a request against Janssen Korea
- by Kim, Jin-Gu May 30, 2022 05:41am
- Samjin has challenged Janssen's patent for the treatment of pulmonary arterial hypertension (Micronized Macitentan). In the past, generic companies have challenged Opsumit patents in all directions, but it has resulted in failure, drawing keen attention to the success of Samjin's challenge. According to the pharmaceutical industry on th
- Company
- The release of Singrix for NIP is expected
- by Moon, sung-ho May 30, 2022 05:41am
- Since the launch of the new government, the shingles vaccine market, called "a vaccine that is filial to parents," has been fluctuating. This is why global pharmaceutical companies are expected to release blockbuster vaccines in Korea in the second half of the year at a time when shingles are widely expected to be included in the NIP.
